Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells

The BH3-mimetic ABT-737 and an orally bioavailable compound of the same class, navitoclax (ABT-263), have shown promising antitumor efficacy in preclinical and early clinical studies. Although both drugs avidly bind Bcl-2, Bcl-x(L), and Bcl-w in vitro, we find that Bcl-2 is the critical target in vi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Mérino, Delphine, Khaw, Seong L., Glaser, Stefan P., Anderson, Daniel J., Belmont, Lisa D., Wong, Chihunt, Yue, Peng, Robati, Mikara, Phipson, Belinda, Fairlie, Walter D., Lee, Erinna F., Campbell, Kirsteen J., Vandenberg, Cassandra J., Cory, Suzanne, Roberts, Andrew W., Ludlam, Mary J. C., Huang, David C. S., Bouillet, Philippe
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2012
Gaiak:
Lymphoid Neoplasia
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3382939/
https://ncbi.nlm.nih.gov/pubmed/22538851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-12-400929
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak